Results 151 to 160 of about 13,841 (201)

Clinical progress note: Varicella Zoster. [PDF]

J Hosp Med
Zhang S, Hersh AL, Jones TW.
europepmc   +1 more source

Public spending on immunisation in Poland. [PDF]

Front Public Health
Seweryn M, Augustyńska J, Kopel J, Jaworski R, Wójcik A, Paradowska-Stankiewicz I, Czech M.   +6 more
europepmc   +1 more source

Real-world effectiveness of recombinant herpes Zoster vaccine: a retrospective, cohort study in Japan. [PDF]

BMC Infect Dis
Ohfuji S, Toyama N, Kondo K, Muto H, Fukushima W.   +4 more
europepmc   +1 more source

Mapping the landscape of herpes zoster vaccine research: A bibliometric analysis. [PDF]

Medicine (Baltimore)
Lu R, Bao S, Zhang J, Yang Y, Wang Y, Zhou Y, Zhou P, Yuan X.   +7 more
europepmc   +1 more source

The effect of shingles vaccination at different stages of the dementia disease course. [PDF]

Cell
Xie M, Eyting M, Bommer C, Ahmed H, Geldsetzer P.   +4 more
europepmc   +1 more source

TLR9 and STING agonists adjuvanted varicella-zoster virus glycoprotein E induced a potent and durable nasal vaccine response. [PDF]

Hum Vaccin Immunother
Yang JX, Lin PY, Tseng JC, Nur Imana Z, Liu YL, Tien CF, Su YS, Tsai WT, Su YW, Chen JK, Huang MH, Chen L, Chuang TH, Yu GY.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Zoster Vaccine Live (Oka/Merck)

Drugs & Aging, 2006
A subcutaneously administered, live, high-titre (18,700-60,000 plaque-forming units per dose) varicella zoster virus (VZV) vaccine (zoster vaccine) of the Oka/Merck strain has been evaluated for the prevention of herpes zoster and the reduction of zoster-associated pain in adults aged > or =60 years.
Dean M, Robinson, Caroline M, Perry
openaire   +3 more sources